DekaBank Deutsche Girozentrale maintained its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, Holdings Channel reports. The fund owned 65,360 shares of the biopharmaceutical company’s stock at the end of the second quarter. DekaBank Deutsche Girozentrale’s holdings in Alnylam Pharmaceuticals were worth $5,143,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. TLP Group LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $380,000. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after buying an additional 31,208 shares in the last quarter. BB Biotech AG raised its stake in shares of Alnylam Pharmaceuticals by 4.2% in the first quarter. BB Biotech AG now owns 1,241,338 shares of the biopharmaceutical company’s stock worth $63,619,000 after buying an additional 50,000 shares in the last quarter. BlackRock Inc. raised its stake in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares in the last quarter. Finally, Hemenway Trust Co LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $235,000. Hedge funds and other institutional investors own 88.99% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (ALNY) opened at 80.37 on Wednesday. The firm’s 50-day moving average is $80.71 and its 200 day moving average is $62.88. The stock’s market cap is $7.37 billion. Alnylam Pharmaceuticals, Inc. has a one year low of $31.38 and a one year high of $86.92.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. The firm had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.05) EPS. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.30) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-maintains-position-in-alnylam-pharmaceuticals-inc-alny/1493893.html.

ALNY has been the subject of a number of research analyst reports. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Piper Jaffray Companies set a $116.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Credit Suisse Group reiterated a “hold” rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 9th. Finally, Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the stock a “buy” rating in a research note on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $81.74.

In other news, major shareholder Sanofi acquired 297,501 shares of the company’s stock in a transaction dated Wednesday, May 31st. The shares were acquired at an average price of $71.87 per share, with a total value of $21,381,396.87. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Akshay Vaishnaw sold 11,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total transaction of $825,000.00. Following the sale, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The disclosure for this sale can be found here. 4.30% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.